Infantile Neuroaxonal Dystrophy (INAD)
Overview
Infantile neuroaxonal dystrophy (INAD) is a rare disease that causes fat substances (lipids) to build up on nerves. It affects nerve signals, leading to a gradual loss of muscle control, vision, speech and intellectual development. These symptoms typically appear in infancy but may occur as late as adolescence.
An inherited gene change (mutation) causes INAD. It’s a type of lipid storage disorder. Unfortunately, there isn’t a cure for this life-threatening condition.
What does “infantile neuroaxonal dystrophy” mean?
You may better understand this disease when you break down each word’s meaning:
Infantile: INAD is present at birth (a congenital disease). Symptoms typically appear during infancy and before a child is 3 years old.
Neuroaxonal: The disease affects axons in nerve cells. Axons carry messages from your brain to the rest of your body.
Dystrophy: Dystrophy is the medical term for disorders that cause tissues, organs and muscles to waste away.
What are the types of INAD?
Infantile neuroaxonal dystrophy is the most common type. Healthcare providers may call it the classic form of INAD. As the name implies, symptoms are evident during infancy.
With atypical INAD (aNAD), symptoms appear around age 4, or more rarely, as late as the teen years. Your child may have speech delays or appear to have autism spectrum disorder. The disease progression is slower.
Symptoms
With classic INAD, your infant is often on track for normal child development for the first six months to three years of life. Then, they slowly begin to lose acquired skills like sitting, crawling, walking and talking. This regression is often due to muscle wasting, which leads to low muscle tone (hypotonia). Your child may appear floppy, especially in their trunk area. As the disease progresses, muscle stiffness or spasticity occurs.
Children with INAD may also experience:
Ataxia (coordination and balance problems).
Difficulty swallowing (dysphagia).
Hearing loss.
Inability to hold up or control their heads.
Loss of cognitive function that leads to dementia.
Seizures.
Speech problems (dysarthria) due to muscle weakness.
Squinting, wobbly eye movements (nystagmus) or other problems like loss of vision.
Infants with INAD often have distinct facial changes noticeable at birth, such as:
Crossed eyes (strabismus).
Large, low-setting ears.
Prominent forehead.
Small nose or jaw.
Causes
Children with INAD inherit a changed or mutated PLA2G6 gene from each parent. This gene helps make an enzyme (a type of protein) called A2 phospholipase that breaks down fats called phospholipids. This type of fat metabolism keeps nerve cells intact so they function properly.
In children with INAD, the changed PLA2G6 gene hinders enzyme production and function. Sphere-shaped substances called spheroid bodies build up on nerves. These deposits often accumulate on nerve endings that connect to their eyes, muscles and skin. Iron may also build up on their brain.
Diagnosis
If this disease runs in your family, a prenatal test can determine whether a developing fetus has inherited the mutated gene. A chorionic villus sampling (CVS) test checks placenta cells for the genetic mutation.
Tests for infants, children and adults include:
Blood test to look for the mutated PLA2G6 gene. A genetic test identifies the disease in 8 of 10 children with INAD.
Electroencephalogram (EEG) to look for seizure activity.
MRI to look for changes to the brain.
Nerve conduction test like an electromyogram.
Skin biopsy or a biopsy on nerves or tissue to look for spheroid bodies in nerve axons.
Treatment
There isn’t a medical treatment or cure for infantile neuroaxonal dystrophy. Treatments focus on easing symptoms to keep your child comfortable. These therapies include:
Anticonvulsants (seizure medications).
Feeding tube (enteral nutrition).
Medications to ease stiff muscles.
Pain relievers.
Physical therapy and proper positioning to support a child’s head and weakened muscles.
Sedatives.
Medical experts are conducting research and clinical trials to find new ways to stop the disease progression and potentially cure INAD. Potential therapies in development include:
Enzyme replacement therapy.
Gene therapy.
Type of Doctor Department : A pediatric neurologist
.jpg)
Comments
Post a Comment